Lisa Ricciardi: So, Charles, it’s Lisa. I’ll take the first part of it, which is to say as we look at the grant opportunities in the two general areas we’re looking in. The larger trials are currently not funded by much grant support. The expectation is, you have access to private investors or the capital markets. And so, I will say going forward, while it would be wonderful to have another $170 million in grant funding, we’re looking at much smaller kinds of grants. So I would guide toward different kind of expectations going forward based on where we are in the clinic. I’ll turn it back to Andy for your questions about the expense coverage.
Andrew Einhorn: Yes. Thanks, Charles. The grant revenue in 2022 covered approximately half the operating expenses that we have. In mind you, the trials that we’re conducting right now with the exception of the MAGNIFY trial in dry AMD, all have grant funding supporting them in one way, shape or form. And in terms of where this money gets put on the balance sheet and so forth, when we incur eligible expenses, we draw on our grants and we get reimbursed by the NIA or whomever fairly almost immediately. When we pay a milestone or upfront payment to a CRO, for example, we’ll draw that money and that gets — and the grant revenue then gets hung up on the balance sheet as deferred revenue and then will be taken into — recognized as income as the trial progresses and as work is done. That answer your questions?
Charles Duncan: Yes, it does. Thank you for taking our questions. Good luck for the near term milestones.
Operator: Our next question comes from Jay Olson from Oppenheimer. Please go ahead. Your line is open.
Jay Olson: Hey, congrats on all the progress and thanks for taking the questions. Can you talk about the proteomic data that you have coming up at ADPD and what investors should be looking forward in terms of how it supports CE1812 mechanism in Alzheimer’s? And then anything else you think investors should look out for ADPD that may have reacross to Cognition? And then I’m going to follow-up on updates.
Lisa Ricciardi: Terrace, Jay. Good morning. Great to hear from you. It’s another exciting year, last year at AAIC. We presented data here, Mary, have some more data. I’ll let Tony take you through what it is. We can discuss the data will be released in a week and a half and then the posters will be available. But at a high level, Tony?
Tony Caggiano: Sure. So we presented data last year from the first 24 patients of our Phase 2 SHINE study and from the START study, which was an imaging study we conducted at Yale. What’s being presented this year at ADPD is a meta-analysis of the two studies. So these are two nearly identical studies with same doses, same patients. There’s a powerful way to cross the two data sets and see which signals of drug exposure and effect come through both studies. So this is giving us good candidate biomarkers to follow in the future for treatment effect. As Lisa mentioned, we haven’t released details at this point on which proteins those are and so forth. You can see that on the poster and we’ll be able to distribute that when it comes up.
Jay Olson: Okay, great. Thank you. We’ll look forward to that. And then just on dry AMD, are there any human genetic data showing the involvement of the σ-2 receptor in dry AMD? And have you had any patients in your Alzheimer’s study who also had dry AMD and showed efficacy signals that you could detect there? And then finally, where do you think CT1812 is an oral drug to fit into the treatment landscape of dry AMD, especially in particular combination regimens? Thank you.
